Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms

Zhang,Wenjuan; Qi,Jiaqian; Zhao,Shixiang; Shen,Wenhong; Dai,Lan; Han,Wei; Huang,Man; Wang,Zhaoyue; Ruan,Changgeng; Wu,Depei; Han,Yue

doi:10.3892/ol.2017.6459

Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms

Authors:
- Wenjuan Zhang
- Jiaqian Qi
- Shixiang Zhao
- Wenhong Shen
- Lan Dai
- Wei Han
- Man Huang
- Zhaoyue Wang
- Changgeng Ruan
- Depei Wu
- Yue Han
View Affiliations

Affiliations: Department of Haematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Haematology, Suzhou, Jiangsu 215006, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/ol.2017.6459
Pages: 2531-2536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Microparticles (MPs) are small membrane vesicles that are classified into subcategories based on their origin, such as platelet‑derived MPs (PMPs), endothelial MPs (EMPs), red blood cell MPs (RMPs) and tissue factor MPs (TF + MPs). Philadelphia chromosome‑negative myeloproliferative neoplasms (Ph‑MPN) are disorders characterized by abnormal haematopoiesis, thrombosis and the JAK2V617F mutation. MPs are biomarkers for procoagulant state in cancer patients, but their relevance in patients with Ph‑MPN was unclear. The present study aimed to measure MP variation in MPN patients and evaluate association with the JAK2V617F mutation and with thrombosis and splenomegaly. In total, 92 patients with MPN were enrolled in the present study, including 60 with essential thrombocythaemia (ET), 20 with polycythaemia vera (PV), and 12 with primary myelofibrosis (PMF). RMPs, PMPs, TF + MPs and EMPs were measured by flow cytometry. The levels of RMPs, PMPs, EMPs and TF + MPs in patients with Ph‑MPN were all found to be significantly increased compared with controls (P<0.05). Additionally, the levels of all four types of MPs in the PMF group were significantly increased compared with the PV group (P<0.05), and the level of RMPs in the PMF group was significantly increased compared with the ET group (P<0.05). MP levels were increased in the Ph‑MPN patients with thrombosis compared with patients without thrombosis (P<0.05). MP levels were increased in Ph‑MPN patients with splenomegaly compared with patients without splenomegaly (P<0.05). The level of PMPs in patients with the JAK2V617F mutation was increased compared with patients without the mutation (P<0.05). In conclusion, the present study showed that MPs are associated with Ph‑MPN pathogenesis, and may promote thrombosis.

View Figures

View References

1	Tefferi A and Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 22:14–22. 2008. View Article : Google Scholar : PubMed/NCBI
2	Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jimenez A, Albizua E, Burgaleta C, Gilsanz F and Martinez-Lopez J: Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol. 161:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
3	Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
4	Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061. 2005. View Article : Google Scholar : PubMed/NCBI
5	Tefferi A: Polycythemi a vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 87:285–293. 2012. View Article : Google Scholar : PubMed/NCBI
6	Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G and Barosi G: Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 115:778–782. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cheung B, Radia D, Pantelidis P, Yadegarfar G and Harrison C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol. 132:244–245. 2006. View Article : Google Scholar : PubMed/NCBI
8	Finazzi G, Rambaldi A, Guerini V, Carobbo A and Barbui T: Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 92:135–136. 2007. View Article : Google Scholar : PubMed/NCBI
9	Willms A, Müller C, Julich H, Klein N, Schwab R, Güsgen C, Richardsen I, Schaaf S, Krawczyk M, Krawczyk M, et al: Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget. 7:30867–30875. 2016.PubMed/NCBI
10	Tseng CC, Wang CC, Hsiao CC, Lu HI, Leu S, Chang HC, Huang KT, Fang WF, Chen YM, Liu SF, et al: Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. Tumour Biol. 37:11873–11882. 2016. View Article : Google Scholar : PubMed/NCBI
11	Campello E, Zanetto A, Spiezia L, Radu CM, Gavasso S, Ferrarese A, Farinati F, Senzolo M and Simioni P: Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res. 143:118–121. 2016. View Article : Google Scholar : PubMed/NCBI
12	Owens AP III and Mackman N: Microparticles in hemostasis and thrombosis. Circ Res. 108:1284–1297. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC and Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 15:6830–6840. 2009. View Article : Google Scholar : PubMed/NCBI
14	Morel O, Luca F, Grunebaum L, Jesel L, Meyer N, Desprez D, Robert S, Dignat-George F, Toti F, Simon C and Goichot B: Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes (Lond). 35:1479–1486. 2011. View Article : Google Scholar : PubMed/NCBI
15	Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061. 2005. View Article : Google Scholar : PubMed/NCBI
16	Boulanger CM, Amabile N and Tedgui A: Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension. 48:180–186. 2006. View Article : Google Scholar : PubMed/NCBI
17	Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N and Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood. 105:1734–1741. 2005. View Article : Google Scholar : PubMed/NCBI
18	Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH and Francis JL: Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation. J Thromb Haemost. 6:1517–1524. 2008. View Article : Google Scholar : PubMed/NCBI
19	Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D and Dubois C: Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 206:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
20	Weiss HJ: Scott syndrome: A disorder of platelet coagulant activity. Semin Hematol. 31:312–319. 1994.PubMed/NCBI
21	Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA and Weltermann A: Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 97:119–123. 2007.PubMed/NCBI
22	Rodriguez P Garcia, Eikenboom HC, Tesselaar ME, Huisman MV, Nijkeuter M, Osanto S and Bertina RM: Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res. 126:345–349. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ma G, Liu F, Lv L, Gao Y and Su Y: Increased promyelocytic-derived microparticles: A novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol. 92:645–652. 2013. View Article : Google Scholar : PubMed/NCBI
24	Tesselaar ME, Romijn FP, van der Linden IK, Prins FA, Bertina RM and Osanto S: Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost. 5:520–527. 2007. View Article : Google Scholar : PubMed/NCBI
25	Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE and Falanga A: Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 94:911–918. 2009. View Article : Google Scholar : PubMed/NCBI
26	Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B and Abgrall JF: Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 126:238–242. 2010. View Article : Google Scholar : PubMed/NCBI
27	Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S and Simioni P: Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 127:473–477. 2011. View Article : Google Scholar : PubMed/NCBI
28	Randhawa J, Ostojic A, Vrhovac R, Atallah E and Verstovsek S: Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 5:432012. View Article : Google Scholar : PubMed/NCBI
29	Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, Do KM, Kim EJ, Ye BJ, Song MK, et al: Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: A multicenter study from Korea. Clin Lymphoma Myeloma Leuk. 12:70–75. 2012. View Article : Google Scholar : PubMed/NCBI
30	Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR and Cattaneo M: Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. Thromb Res. 124:409–417. 2009. View Article : Google Scholar : PubMed/NCBI
31	Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L and Santini V: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 93:41–48. 2008. View Article : Google Scholar : PubMed/NCBI
32	Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B and Falanga A: Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol. 89:68–73. 2014. View Article : Google Scholar : PubMed/NCBI